Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bipolar Androgen Therapy in mCRPC
NCT04424654Phase 2Completed
- Sponsor
- Hospital Sírio-Libanês
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of testosterone cypionate in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hospital Sírio-Libanês. Started Sep 2020; status: completed.
02
Drugs
testosterone cypionate
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04424654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04424654.